Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Guidance
  • Health Care
  • Movers
  • News

What’s Going On With Stress Hormone Modulator-Focused Corcept Therapeutics’ Stock Friday?

By Vandana Singh
February 16, 12:25 PM
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.

CORT

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?

By Vandana Singh
February 15, 4:39 PM
Organon exceeds Q4 2023 revenue expectations, reaching $1.6 billion. Women's Health thrives with 7% revenue increase, driven by Follistim AQ's 63% growth. Biosimilar revenue surges by 49%.

OGN

Read More
3 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh
February 15, 4:29 PM
Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

ALNY

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today?

By Vandana Singh
February 15, 4:25 PM
Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD Deficiency patients.

APLT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Equities
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas
  • Upgrades

Competitor Exit A Boom For Respiratory Device-Focused Inogen, Earns Analyst Upgrade

By Vandana Singh
February 15, 3:30 PM
Impact of Philips' decision to halt CPAP device sales in the U.S. and its potential market implications. William Blair sees a significant opportunity for Inogen to reclaim market share.

INGN

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Movers
  • News
  • Price Target
  • Trading Ideas

Monte Rosa Therapeutics’ AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst

By Vandana Singh
February 15, 3:05 PM
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.

GLUE

Read More
2 minute read
  • Health Care
  • Hedge Funds
  • Tech
  • Top Stories

Ray Dalio’s Bridgewater Makes Waves: Q4 Unveils Strategic Shifts With New Investments, Sector Expansion In Tech

By Surbhi Jain
February 15, 2:39 PM
Bridgewater Associates, founded by Ray Dalio, made notable changes to its portfolio in Q4 2023. New bets, exits, increased stakes offer insights into its investment strategy.

AAPL

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Reiteration
  • Trading Ideas

West Pharmaceutical’s 2024 Outlook Cautious, Analysts Remain Optimistic

By Vandana Singh
February 15, 2:17 PM
West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth, emphasizing inventory management strategies.

WST

Read More
3 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Markets
  • News
  • Top Stories

UK Becomes First Major Market for Eli Lilly’s Mounjaro Prefilled Pen For Tackling Obesity

By Vandana Singh
February 15, 11:09 AM
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients.

LLY

Read More
2 minute read
  • General
  • Health Care
  • Large Cap
  • Movers
  • News

What’s Going On With Recursion Pharmaceuticals Stock On Thursday?

By Vandana Singh
February 15, 11:03 AM
Recursion Pharmaceuticals' approach to drug discovery. NVIDIA's $75.9 million stake amplifies the impact of generative AI in identifying innovative treatments.

NVDA

Posts pagination

Previous 1 … 55 56 57 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service